NeoGenomics Integrates with Epic to Enhance Oncology Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy NEO?
Source: Newsfilter
- Efficiency Enhancement: NeoGenomics' oncology testing portfolio is now available through the Epic Aura system, allowing physicians to order and view results on the same platform, thereby streamlining the testing process and accelerating clinical decisions.
- Increased Adoption Rates: This integration is expected to drive a 20-30% increase in test adoption rates at hospitals and health systems, facilitating faster treatment initiation for cancer patients and significantly improving treatment timelines.
- Digital Health Strategy Advancement: The integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity between community oncology practices and large health systems, thereby promoting scalable precision oncology adoption.
- Future Diagnostic Capabilities: The
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 9.070
Low
12.00
Averages
14.00
High
16.00
Current: 9.070
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeoGenomics Q1 2026 Earnings Call Insights and Guidance Update
- Significant Revenue Growth: NeoGenomics reported total revenue of $186.7 million for Q1, reflecting an 11% year-over-year increase that exceeded expectations, showcasing the company's strong market performance and growth potential.
- Portfolio Optimization: The five NGS products launched in 2023 contributed 25% of clinical revenue, driving a 26% increase in NGS revenue, which now represents one-third of clinical revenue, indicating a strategic shift towards higher-value offerings.
- Upgraded Full-Year Guidance: Following the MolDX approval of PanTracer Liquid in March, NeoGenomics raised its full-year revenue guidance to a range of $797 million to $803 million, reflecting management's confidence in future performance.
- Market Competitive Advantage: With a 25% market share in diagnostics and therapy selection, the company has enhanced test adoption through the development of over 330 interfaces, which is expected to drive future revenue growth and market share expansion.
See More
NeoGenomics NEO Q2 2025 Earnings Transcript
See More
NeoGenomics Set to Announce Q1 Earnings on April 28
- Earnings Announcement Schedule: NeoGenomics is set to release its Q1 2023 earnings on April 28 after market close, with consensus EPS estimated at $0.00 and revenue expected at $184.48 million, reflecting a 9.8% year-over-year growth.
- Historical Performance Review: Over the past two years, NeoGenomics has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, indicating strong financial performance and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and five downward adjustments, while revenue estimates have experienced no upward revisions and seven downward adjustments, suggesting a cautious market outlook on the company's future performance.
- Future Outlook: NeoGenomics has set a revenue target of $793 million to $801 million for 2026, as initiatives like RaDaR ST and PanTracer gain traction, which is expected to further drive the company's growth.
See More
NeoGenomics Integrates with Epic to Enhance Oncology Testing
- Efficiency Enhancement: NeoGenomics' oncology testing portfolio is now available through the Epic Aura system, allowing physicians to order and view results on the same platform, thereby streamlining the testing process and accelerating clinical decisions.
- Increased Adoption Rates: This integration is expected to drive a 20-30% increase in test adoption rates at hospitals and health systems, facilitating faster treatment initiation for cancer patients and significantly improving treatment timelines.
- Digital Health Strategy Advancement: The integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity between community oncology practices and large health systems, thereby promoting scalable precision oncology adoption.
- Future Diagnostic Capabilities: The
See More
NeoGenomics to Present New Research at AACR Annual Meeting
- Research Presentation: NeoGenomics will showcase eight scientific posters and one oral presentation at the 2026 AACR Annual Meeting, emphasizing its capabilities in integrating clinical and genomic insights through its Oncology Data Solutions platform, which is expected to advance precision medicine.
- Clinical Data Integration: By linking laboratory testing with clinical data, NeoGenomics has demonstrated its ability to drive deeper characterization of biomarker prevalence and evaluation of testing concordance, thereby providing critical clinical insights for oncology therapy development.
- Partnership Collaborations: The company's collaborations with biopharma partners have enabled the development of compelling research, with CEO Tony Zook stating that these findings will directly enhance therapy development and create more options for providers and patients.
- Future Outlook: NeoGenomics' research not only showcases its leadership in the oncology field but also has the potential to promote the development and commercialization of novel oncology therapies by facilitating translational research into clinical applications.
See More
NeoGenomics to Report Q1 2026 Financial Results on April 28
- Earnings Release Schedule: NeoGenomics will report its Q1 2026 financial results after the U.S. market closes on April 28, reflecting the company's commitment to transparency and investor communication.
- Webcast and Conference Call: Management will host a live webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights, aiming to enhance investor understanding and confidence in the company's performance.
- New Quarterly Call Protocol: Starting with Q1 2026, NeoGenomics will hold quarterly earnings calls after market close, allowing for follow-up discussions before the next trading day, thereby improving information dissemination efficiency.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services, further solidifying its leadership in precision medicine.
See More
NeoGenomics Q1 2026 Earnings Call Insights and Guidance Update
- Significant Revenue Growth: NeoGenomics reported total revenue of $186.7 million for Q1, reflecting an 11% year-over-year increase that exceeded expectations, showcasing the company's strong market performance and growth potential.
- Portfolio Optimization: The five NGS products launched in 2023 contributed 25% of clinical revenue, driving a 26% increase in NGS revenue, which now represents one-third of clinical revenue, indicating a strategic shift towards higher-value offerings.
- Upgraded Full-Year Guidance: Following the MolDX approval of PanTracer Liquid in March, NeoGenomics raised its full-year revenue guidance to a range of $797 million to $803 million, reflecting management's confidence in future performance.
- Market Competitive Advantage: With a 25% market share in diagnostics and therapy selection, the company has enhanced test adoption through the development of over 330 interfaces, which is expected to drive future revenue growth and market share expansion.
See More
NeoGenomics NEO Q2 2025 Earnings Transcript
See More
NeoGenomics Set to Announce Q1 Earnings on April 28
- Earnings Announcement Schedule: NeoGenomics is set to release its Q1 2023 earnings on April 28 after market close, with consensus EPS estimated at $0.00 and revenue expected at $184.48 million, reflecting a 9.8% year-over-year growth.
- Historical Performance Review: Over the past two years, NeoGenomics has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, indicating strong financial performance and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and five downward adjustments, while revenue estimates have experienced no upward revisions and seven downward adjustments, suggesting a cautious market outlook on the company's future performance.
- Future Outlook: NeoGenomics has set a revenue target of $793 million to $801 million for 2026, as initiatives like RaDaR ST and PanTracer gain traction, which is expected to further drive the company's growth.
See More
NeoGenomics Integrates with Epic to Enhance Oncology Testing
- Efficiency Enhancement: NeoGenomics' oncology testing portfolio is now available through the Epic Aura system, allowing physicians to order and view results on the same platform, thereby streamlining the testing process and accelerating clinical decisions.
- Increased Adoption Rates: This integration is expected to drive a 20-30% increase in test adoption rates at hospitals and health systems, facilitating faster treatment initiation for cancer patients and significantly improving treatment timelines.
- Digital Health Strategy Advancement: The integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity between community oncology practices and large health systems, thereby promoting scalable precision oncology adoption.
- Future Diagnostic Capabilities: The
See More
NeoGenomics to Present New Research at AACR Annual Meeting
- Research Presentation: NeoGenomics will showcase eight scientific posters and one oral presentation at the 2026 AACR Annual Meeting, emphasizing its capabilities in integrating clinical and genomic insights through its Oncology Data Solutions platform, which is expected to advance precision medicine.
- Clinical Data Integration: By linking laboratory testing with clinical data, NeoGenomics has demonstrated its ability to drive deeper characterization of biomarker prevalence and evaluation of testing concordance, thereby providing critical clinical insights for oncology therapy development.
- Partnership Collaborations: The company's collaborations with biopharma partners have enabled the development of compelling research, with CEO Tony Zook stating that these findings will directly enhance therapy development and create more options for providers and patients.
- Future Outlook: NeoGenomics' research not only showcases its leadership in the oncology field but also has the potential to promote the development and commercialization of novel oncology therapies by facilitating translational research into clinical applications.
See More
NeoGenomics to Report Q1 2026 Financial Results on April 28
- Earnings Release Schedule: NeoGenomics will report its Q1 2026 financial results after the U.S. market closes on April 28, reflecting the company's commitment to transparency and investor communication.
- Webcast and Conference Call: Management will host a live webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights, aiming to enhance investor understanding and confidence in the company's performance.
- New Quarterly Call Protocol: Starting with Q1 2026, NeoGenomics will hold quarterly earnings calls after market close, allowing for follow-up discussions before the next trading day, thereby improving information dissemination efficiency.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services, further solidifying its leadership in precision medicine.
See More
